Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.71 |
| ▸ | DRD4 | P21917 | 10/20 | 0.71 |
| ▸ | DRD3 | P35462 | 10/20 | 0.71 |
| ▸ | CCR3 | P51677 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6768518 | 1.00 | DRD2 (0.71) | DRD2DRD4DRD3CCR3ALDH1A1 | |
| SCHEMBL6769014 | 0.97 | DRD2 (0.77) | DRD2DRD4DRD3CCR3ALDH1A1 | |
| SCHEMBL6769011 | 0.97 | DRD2 (0.77) | DRD2DRD4DRD3CCR3ALDH1A1 | |
| SCHEMBL6765093 | 0.86 | DRD2 (0.94) | DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL6765090 | 0.86 | DRD2 (0.94) | DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL6767727 | 0.84 | DRD2 (0.62) | DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL6767729 | 0.84 | DRD2 (0.62) | DRD2DRD4DRD3ALDH1A1 | |
| SCHEMBL6764514 | 0.84 | DRD2 (0.94) | DRD2DRD4DRD3 | |
| SCHEMBL6764513 | 0.84 | DRD2 (0.94) | DRD2DRD4DRD3 | |
| SCHEMBL6767119 | 0.83 | DRD2 (1.00) | DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723724-B2 | PSYCHOLOGICAL DISORDERS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-04-20 | — | — | US | claimed |
| US-20020119983-A1 | Novel isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2002-08-29 | — | — | US | claimed |
| US-6723724-B2 | PSYCHOLOGICAL DISORDERS | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2004-04-20 | — | — | US | disclosed |
| US-20020119983-A1 | Novel isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2002-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119983-A1 | Novel isoxazolylalkylpiperazine derivatives having selective biological activity at dopamine D3 or D4 receptor, and preparation thereof | DRD4, DRD3, DRD2 | DRD2 3/4885DRD4 1/4885DRD3 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.